Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401379 | 0.91 | SMO (0.72) | SMOMAPTKDM4EKMT2AMEN1 | |
| SCHEMBL404013 | 0.91 | SMO (0.57) | SMOMAPTKDM4ECHRM1ALDH1A1 | |
| SCHEMBL402625 | 0.90 | SMO (0.60) | SMOMAPTKMT2AMEN1LMNA | |
| SCHEMBL400560 | 0.90 | SMO (0.61) | SMOMAPTKDM4EKMT2AMEN1 | |
| SCHEMBL404000 | 0.88 | SMO (0.61) | SMOMAPTKDM4ECHRM5CHRM1 | |
| SCHEMBL10238332 | 0.88 | SMO (0.58) | SMOMAPTKDM4EGAAKMT2A | |
| SCHEMBL404073 | 0.87 | SMO (0.59) | SMOMAPTKDM4EKMT2AMEN1 | |
| SCHEMBL403779 | 0.87 | SMO (0.55) | SMOMAPTCHRM1KMT2AMEN1 | |
| SCHEMBL4971602 | 0.86 | SMO (0.52) | SMOMAPTKDM4ECHRM1GAA | |
| SCHEMBL399857 | 0.86 | MAPT (0.57) | SMOMAPTCHRM5CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | claimed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | claimed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | SHH, GLI1, SMO | SMO 3/4885MAPT 2726/4885KDM4E 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.